More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease ...
FRANKFURT — Swiss drugmaker Roche (ROG.S), said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious hospital infections into the third and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results